|Year : 2015 | Volume
| Issue : 1 | Page : 127-129
Eosinophilia induced by clozapine: A report of two cases and review of the literature
Jitender Aneja, Nidhi Sharma, Sudhir Mahajan, Subho Chakrabarti, Sandeep Grover
Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
|Date of Web Publication||27-Feb-2015|
Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
Source of Support: None, Conflict of Interest: None
Clozapine, an atypical antipsychotic, has been used in the treatment of schizophrenia and other psychotic disorders. Although it has good therapeutic effect but many a time it use is overridden by the associated adverse effects which range from minor to severe life-threatening events. There has been extensive literature for severe side effects like leukocytosis but limited data are available for transient eosinophilia. Here, we present two cases of benign transient eosinophilia and discuss the importance of recognizing eosinophilia while using clozapine.
Keywords: Clozapine, eosinophilia, side effects
|How to cite this article:|
Aneja J, Sharma N, Mahajan S, Chakrabarti S, Grover S. Eosinophilia induced by clozapine: A report of two cases and review of the literature. J Family Med Prim Care 2015;4:127-9
|How to cite this URL:|
Aneja J, Sharma N, Mahajan S, Chakrabarti S, Grover S. Eosinophilia induced by clozapine: A report of two cases and review of the literature. J Family Med Prim Care [serial online] 2015 [cited 2019 May 24];4:127-9. Available from: http://www.jfmpc.com/text.asp?2015/4/1/127/152269
| Introduction|| |
Since its introduction, clozapine has been associated with haematological abnormalities, with most common abnormality being leucopenia, and other less commonly reported haematological abnormalities include agranulocytosis, neutropenia, thrombocytopenia, leukocytosis, and thrombocytothaemia.  However, there are few reports of eosinophilia associated with the use of clozapine. ,,,,
In this report, we present two cases of eosinophilia associated with clozapine and discuss the clinical implications of detection of eosinophilia in patients receiving clozapine.
| Case 1|| |
Miss X, a 32-year female, diagnosed with schizoaffective disorder, hypothyroidism, drug induced polycystic ovary disease, and migraine presented with a relapse while on Quetiapine 800 mg/day, Lithium Carbonate 900 mg/day, Thyroxine 150 mcg/day, Amitriptyline 75 mg/day, and Metformin 1 g/day. Her treatment history revealed that she had not responded to three antipsychotic trials in the past and resultantly was considered for clozapine. Preclozapine investigations in the form of heamogram, liver function test, renal function test, fasting blood glucose level, electroencephalogram and electrocardiogram did not reveal any abnormality. However, lipid profile was deranged for which she was advised dietary modifications, regular physical activities; metformin was continued in consultation with the endocrinologist. Clozapine was started at the dose of 25 mg/day and her heamogram was monitored. After about 2 weeks (13 th day of clozapine), while she was on clozapine 150 mg/day, her haemogram showed an eosinophil count of 9% with an absolute eosinophil count of 936/cmm. At this time her physical examination did not reveal any rash or any other abnormality to suggest any infection or allergic reaction. In view of the increased eosinophil count, she was investigated further in form of complete blood count, urine microscopic examination and culture, peripheral blood smear for malarial parasite and a chest roentgenogram, all of which were found to be within the normal range except for persistence of increased eosinophil count. Her investigations for impending myocarditis in form of Troponin-T and Creatine Kinase (CK- MB) also did not reveal any abnormality. In view of the response to clozapine and no symptoms suggestive of any infective or allergic pathology, clozapine was continued and the dose was gradually increased to 200 mg/day along with an empirical trial of mebendazole. However, on 26 th day of clozapine her eosinophil count increased to 42% with absolute eosinophil count of 6090/cmm along with leucocytosis (total leucocyte count of 14500/cmm). All other investigations were repeated including evaluation for myocarditis, but no abnormality was noted except for T-wave inversion in leads V1-5. Echocardiography did not reveal any other abnormality. In view of the electrocardiographic changes, clozapine was stopped and she was started on haloperidol. Following stoppage of clozapine her symptoms again worsened, but her eosinophil count reduced to 18% with absolute eosinophil count of 2,880/cmm. In view of the worsening, after a gap of 2 weeks she was restarted on clozapine and dose was increased to 200 mg/day and her eosinophil count was closely monitored. During the initial 2 weeks of re-challenge her eosinophil count fluctuated between 12-15% with absolute eosinophil count varying between 1116-1248/cmm. Later on the eosinophil count settled down to 2-5% and she was continued on clozapine. She is on clozapine for more than a year and have been maintaining well with eosinophil count varying between 2-5%, with no signs of any myocarditis.
| Case 2|| |
Miss Z, 46 years, diagnosed with paranoid schizophrenia presented to the inpatient unit with a relapse. Her treatment history revealed that she had not responded to adequate trials of trifluperazine, risperidone, olanzapine, and haloperidol. In view of the treatment resistance, she was considered for clozapine. Preclozapine investigations in the form of haemogram, liver function test, renal function test, fasting blood glucose level, electroencephalogram, and electrocardiogram did not reveal any abnormality. Her total leucocyte count was 8300/cmm of which 2% leucocytes were eosinophils. She was started on clozapine at the dose of 12.5 mg/day and on fourth day while on 37.5 mg/day of clozapine her eosinophil count increased to 7%. However, there was no evidence of any rash, fever, or infective pathology. Her investigations in the form of liver function test, urine examination (microscopic examination and culture), chest roentgenogram, echocardiography, and electrocardiogram did not reveal any abnormality. She was investigated for ova/cysts in stool, serum immunoglobulin E levels, and antinuclear antibodies to rule out allergic etiology or connective tissue disorder. She tested negative for ova/cysts and serum ANA levels were within normal range but the IgE levels were raised to 3300 IU/ml (N =30-300 IU/ml). In consultation with the Rheumatologist she was empirically given two doses of albendazole 400 mg a week apart. In view of the clinical response to clozapine, she was continued on clozapine and the dose of clozapine was increased to 150 mg/day. Over the next 5 weeks her eosinophil count varied between 5-8%. After this her eosinophil count settled down to 1-2% and she tolerated 150 mg/day of clozapine with no other haematological abnormality. She continues to receive clozapine for 6 months without any increase in eosinophil count.
| Discussion|| |
Eosinophilia has been reported as a rare side effect associated with clozapine. The studies which have carried out surveillance of side effects of clozapine have reported an incidence of transient eosinophilia to vary widely from 0.2-61.7% patients.  Eosinophilia whenever develops is usually seen during the initial phase of treatment with clozapine, usually within first 4 weeks of therapy.  As with other blood dyscrasia with clozapine, various mechanisms have been proposed to be responsible for clozapine associated eosinophilia. Commonly proposed mechanisms include type-I hypersensitivity reaction, which is supported by evaluated IgE levels in few reports  and stimulation of t-lymphocytes. 
Clozapine-associated eosinophilia is understood as two different forms: First transient benign eosinophilia and second eosinophilia with end organ damage. The eosinophilia has been shown to be associated with myocarditis, ,,, pancreatitis, ,,, colitis, ,, toxic hepatitis,  and pleural effusions. , Other reports have also linked eosinophilia to predict neutropenia. 
With regard to the management of clozapine-associated eosinophilia, literature suggests that decision of continuation of clozapine is determined by the presence or the absence of other organ damage. The literature emerging from the case reports suggests that invariably clinicians have opted to stop clozapine in the presence of end organ damage. However, in the absence of end organ damage the eosinophilia is usually benign and transient. Accordingly, whenever eosinophilia is noticed it is important to evaluate the patient for the presence of any specific organ damage and decision making should take the same into account. In occasional cases, authors have also rechallenged patients with clozapine even after an episode of clozapine and have used it successfully with only few cases of recurrence of eosinophilia along with other organ damage.
There are no clear cut monitoring guidelines for eosinophilia while using clozapine. However, clinicians should give due importance to the eosinophil count while reviewing the hemogram.
Both our patients developed eosinophilia during the initial phase of the treatment and further evaluation did not reveal any other organ damage and, hence, clozapine was continued in the second case and in the first case rechallenged with clozapine did not lead to the recurrence of eosinophilia. Our cases add to the existing literature that in the absence of other organ damage clozapine can be continued safely. However, close monitoring should be done.
| References|| |
Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61 Suppl 8:14-7.
Frankenburg FR, Kando J. Eosinophilia, clozapine and pancreatitis. Lancet 1992;340:251.
Stricker BH, Tielens JA. Eosinophilia with clozapine. Lancet 1991;338:1520-1.
Tihonen J, Paanila J. Eosinophilia associated with clozapine. Lancet 1992;399:488.
Banov MD, Tohen M, Friedberg J. High risk of eosinophlia in women treated with clozapine. J Clin Psychiatry 1993;54:466-9.
Schuepbach D, Merlo MC, Kaeser L, Brenner HD. Successful challenge with clozapine in a history of eosinophilia. Int Clin Psychopharmacol 1998;13:33-7.
Hummer M, Sperner-Unterweger S, Kemmler G, Falk M, Kurz M, Oberbauer H, et al
. Does eosinophilia predict clozapine induced neutropenia? Psychopharmacology (Berl) 1996;124:201-4.
Lucht MJ, Rietschel M. Clozapine- induced eosinophilia: Subsequent neutropenia and corresponding allergic mechanisms. J Clin Psychiatry 1998;59:195-7.
Zipris P, Melamed Y, Weizman A, Bleich A. Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies. Isr J Psychiatry Relat Sci 2007;44:54-6.
Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
Merrill DB, Ahmari SE, Bradford JM, Lieberman JA. Myocarditis during clozapine treatment. Am J Psychiatry 2006;163:204-8.
Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: A case series from the New Zealand Intensive Medicines Monitoring Programme. NZ Med J 2008;121:68-75.
Chengappa KN, Pelucio M, Baker RW, Cole D. Recurrent pancreatitis on clozapine re-challenge. J Psychopharmacol 1995;9:381-2.
Garlipp P, Rosenthal O, Haltenhof H, Machleidt W. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: Implications for clinical care, recognition, and management. J Psychopharmacol 2002;16:399-400.
Karmacharya R, Mino M, Pirl WF. Clozapine-induced eosinophilic colitis. Am J Psychiatry 2005;162:1386-7.
Friedberg JW, Frankenburg FR, Burk J, Johnson W. Clozapine caused eosinophilic colitis. Ann Clin Psychiatry 1995;7:97-8.
Hawe R, Bolton JM. Response to clozapine- induced microscopic colitis: A case report and review of the literature. J Clin Psychopharmacol 2008;28:454-5.
Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by clozapine treatment. Am J Psychiatry 1993;150:985-6.
Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, Bezner J, et al
. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998;13:95-8.
Patel JJ, Lisi PA, Lathara Z, Lipchik RJ. Clozapine- induced peripheral and pleural fluid eosinophilia. Ann Pharmacother 2012;46:e4.